
UK launches first Ebola vaccine trial amid outbreak
Regulators in the UK have approved phase-one trials for an Ebola vaccine developed at Oxford, kicking off just eight weeks after an outbreak was declared in the Democratic Republic of Congo. The trial will recruit 50 healthy adults in the UK, with potential trials in Africa, and uses a chimpanzee adenovirus vector carrying a Bundibugyo Ebola gene. Cure/production is by Serum Institute of India. Researchers aim to assess safety and immune response in parallel with other Ebola vaccines, as there are no approved vaccines yet and three other candidates are in development.












